Skip to content

Red flags and safety concerns

TL;DR — Sudden focal neurological loss, a new disabling balance or visual syndrome, or a maximal-at-onset severe headache must be treated as time-critical until stroke and intracranial hemorrhage are excluded. FAST captures common anterior-circulation presentations but misses a meaningful fraction of strokes characterized by balance or eye symptoms; adding BE-FAST reduced missed cases in one emergency-department cohort (Harbison 2003, PMID 12511753; Aroor 2017, PMID 28082668). Transient symptoms are not reassuring: organized urgent assessment and treatment after TIA or minor stroke reduced 90-day recurrent stroke from 10.3% to 2.1% in EXPRESS (Rothwell 2007, PMID 17928046). After diagnosis, any new headache, vomiting, reduced consciousness, neurological worsening, airway change, fever, or hemodynamic instability requires cause-specific reassessment for hemorrhage, edema, hydrocephalus, re-occlusion, seizure, aspiration, or systemic complications. Stroke scores support communication and triage; none safely replaces examination, glucose testing, brain imaging, vascular imaging, or repeated observation.

Emergency symptom patterns

Stroke usually presents as a loss of function with abrupt onset: weakness, numbness, language disturbance, visual loss, neglect, ataxia, diplopia, dysarthria, or impaired consciousness. Positive phenomena—marching tingling, scintillating vision, or rhythmic jerking—raise migraine or seizure but do not exclude ischemia, especially when followed by a persistent negative deficit.

Red-flag pattern Time-critical possibilities Frequent trap
Face droop, unilateral arm/leg weakness, aphasia Anterior-circulation ischemia or hemorrhage Waiting for pain; most ischemic strokes are painless
Sudden diplopia, dysarthria, dysphagia, limb/truncal ataxia Brainstem or cerebellar stroke, basilar occlusion Calling symptoms “vertigo” without gait, eye-movement, cranial-nerve and limb examination
New visual-field loss or monocular blindness Occipital/optic-pathway ischemia, retinal ischemia Mistaking visual loss for ocular fatigue or migraine without defining positive vs negative symptoms
Maximal-at-onset severe headache SAH, ICH, cervical dissection, cerebral venous thrombosis, reversible vasoconstriction Treating pain improvement as diagnostic reassurance
Recurrent stereotyped weakness or dysarthria over hours Unstable perforator disease, capsular warning syndrome, embolic recurrence Labeling multiple brief events “low risk” because each resolved
Seizure with persistent focal deficit Post-ictal paresis, stroke provoking seizure, hemorrhage, venous thrombosis Assuming Todd paresis before imaging
Reduced consciousness without clear cause Basilar occlusion, thalamic stroke, ICH/SAH, seizure, toxic-metabolic disorder NIHSS can underrepresent coma-producing posterior disease

FAST was designed as a simple public and prehospital screen. In a prospective comparison, ambulance use of face-arm-speech testing achieved high diagnostic accuracy and improved recognition relative to less structured referral (Harbison 2003, PMID 12511753). FAST is intentionally incomplete. In an emergency cohort, 14.1% of stroke/TIA cases were FAST-negative; adding balance and eye symptoms as BE-FAST reduced the missed proportion to 4.4%, with many remaining misses due to non-focal symptoms (Aroor 2017, PMID 28082668).

ROSIER combines loss of consciousness/seizure, asymmetric face/arm/leg weakness, speech disturbance, and visual-field defect; in its initial validation, a score >0 had sensitivity 93% and specificity 83% (Nor 2005, PMID 16239179). Performance of all recognition scales changes with case mix and examiner training. A negative score cannot overrule a focal examination.

Posterior-circulation danger

Posterior strokes are disproportionately vulnerable to delay because dizziness, nausea, imbalance, and headache are common benign symptoms. Red flags within an acute vestibular syndrome include inability to stand or walk unaided, direction-changing or vertical nystagmus, skew deviation, a normal head impulse despite continuous vertigo, new unilateral hearing loss, severe occipital/neck pain, and any focal neurological sign.

In a high-risk specialist cohort with continuous acute vestibular syndrome, the three-part HINTS examination was 100% sensitive and 96% specific for stroke; early MRI diffusion was falsely negative in 12% before 48 hours (Kattah 2009, PMID 19762709). This result depends on correct patient selection and examiner expertise: HINTS is not validated for intermittent dizziness, patients without spontaneous nystagmus, or untrained casual use. A normal early MRI does not end reassessment when central signs persist.

Basilar-artery occlusion may fluctuate, progress, or present with coma. Thrombectomy evidence now includes severe basilar occlusion within 12 hours and selected patients at 6–24 hours, so late presentation does not make vascular imaging pointless (Tao 2022, PMID 36239644; Jovin 2022, PMID 36239645).

Transient deficits are active risk signals

TIA is a tissue-based diagnosis after symptoms resolve, not a label that can be safely assigned before excluding hemorrhage, ongoing occlusion, and infarction. ABCD2 uses age, blood pressure, clinical features, duration, and diabetes; validation showed rising short-term stroke risk with increasing score (Johnston 2007, PMID 17258668). It omits vascular imaging, recurrent events, carotid stenosis, atrial fibrillation, and diffusion lesions; low scores can therefore coexist with a high-risk mechanism.

The EXPRESS sequential population study showed that reducing delay to clinic assessment and immediate preventive treatment reduced 90-day recurrent stroke from 10.3% to 2.1% (adjusted hazard ratio 0.20), without increasing intracerebral hemorrhage (Rothwell 2007, PMID 17928046). The number is a systems result: urgency, diagnostic access, and mechanism-directed treatment mattered together.

Capsular warning syndrome—recurrent stereotyped lacunar motor or sensorimotor attacks clustered over a short interval—carried a 7-day stroke risk of 60% in a population-based study, with all strokes occurring within 48 hours of the second TIA (Paul 2012, PMID 22972645). Repetition is a warning, not evidence of a benign mimic.

Short-course dual antiplatelet therapy reduces early recurrence in selected non-cardioembolic minor stroke/high-risk TIA but increases bleeding as exposure lengthens. CHANCE found 90-day stroke in 8.2% with clopidogrel plus aspirin versus 11.7% with aspirin in a Chinese population, without more moderate/severe hemorrhage (Wang 2013, PMID 23803136). POINT found major ischemic events in 5.0% versus 6.5%, but major hemorrhage in 0.9% versus 0.4% (Johnston 2018, PMID 29766750). Ticagrelor plus aspirin in THALES reduced stroke/death at 30 days from 6.6% to 5.5%, while severe bleeding rose from 0.1% to 0.5% (Johnston 2020, PMID 32668111). These regimens are not interchangeable with anticoagulation for atrial fibrillation and should not precede exclusion of hemorrhage.

Dangerous mimics and stroke look-alikes

Mimic / alternate vascular diagnosis Clues Safety consequence
Hypoglycemia Sweating, altered behavior, seizure, focal deficit Test glucose immediately; correction does not exclude concurrent stroke if deficit persists
Seizure / post-ictal deficit Witnessed convulsion, gaze deviation, positive motor activity Image for provoking stroke/hemorrhage; consider EEG if unexplained fluctuation
Migraine aura Gradual spread, positive visual/sensory symptoms, prior identical episodes First, abrupt, prolonged, or negative deficits require vascular exclusion
Functional neurological disorder Internal inconsistency on expert examination A diagnosis requiring positive features, not normal CT alone
Toxic-metabolic encephalopathy Diffuse rather than focal dysfunction Focal signs still require brain and vascular imaging
Cervical artery dissection New unilateral neck/head pain, partial Horner syndrome, pulsatile tinnitus, posterior symptoms Image cervical and intracranial arteries; minor trauma history may be relevant
Cerebral venous thrombosis Progressive or thunderclap headache, seizure, papilledema, focal deficit; pregnancy/puerperium or prothrombotic exposure CT venography or MR venography; a normal non-contrast CT does not exclude it

Among 72,582 alteplase-treated suspected strokes in a US quality registry, 3.5% were ultimately diagnosed as mimics; symptomatic ICH occurred in 0.4% of mimics versus 3.5% of ischemic strokes (Ali-Ahmed 2019, PMID 31412730). This supports rapid treatment when a disabling ischemic stroke remains the leading diagnosis after appropriate assessment; it does not justify indiscriminate thrombolysis or skipping hemorrhage exclusion.

Cervical dissection can produce ischemia after head or neck pain and can be missed if only intracranial vessels are imaged. CADISS found recurrent stroke uncommon and no significant difference between antiplatelet and anticoagulant strategies (Markus 2019, PMID 30801621); the urgent issue is recognizing the diagnosis and its arterial territory, not assuming anticoagulation is always superior.

The 2024 AHA statement describes cerebral venous thrombosis as a cause of headache, seizure, focal deficit, encephalopathy, intracranial hypertension, venous infarction, and hemorrhage requiring venous imaging (Saposnik 2024, PMID 38284265). In stable CVT after the acute phase, RE-SPECT CVT reported no recurrent venous thromboembolism in either dabigatran or warfarin groups and one versus two major bleeds, but the trial was small (n=120) and excluded some severe presentations (Ferro 2019, PMID 31479105).

Thunderclap headache and hemorrhage

The Ottawa SAH Rule is highly sensitive in its defined population but only 15.3% specific; it should not be applied to patients with neurological deficit or outside its enrollment criteria (Perry 2013, PMID 24065011). Modern CT within 6 hours was 100% sensitive in a prospective cohort under expert-reading conditions, but overall sensitivity fell to 92.9% when later scans were included (Perry 2011, PMID 21768192). Incorrect onset time, anemia, poor image quality, or persistent high suspicion changes the post-CT pathway (subarachnoid hemorrhage).

On confirmed ICH, a CTA spot sign enriches for hematoma expansion but is not required for deterioration: PREDICT reported 51% sensitivity and 85% specificity for significant growth (Demchuk 2012, PMID 22405630). Anticoagulant reversal and blood-pressure treatment should not wait for a spot sign when otherwise indicated (intracerebral hemorrhage; Greenberg 2022, PMID 35579034).

Deterioration after ischemic stroke

New finding Leading causes Immediate safety checks
Headache, vomiting, acute hypertension, reduced consciousness after thrombolysis/thrombectomy Symptomatic intracranial hemorrhage Stop infusion if running; urgent CT, CBC/coagulation/fibrinogen; reversal pathway
Recurrent or worsening deficit Re-occlusion, incomplete reperfusion, new-territory embolus, edema, hemorrhage, seizure NIHSS, glucose, CT/CTA; thrombectomy-team review where relevant
Progressive drowsiness over 1–5 days after large MCA infarct Malignant edema and herniation CT, airway, osmotherapy as bridge, immediate neurosurgical discussion
Tongue/lip swelling during or after alteplase Orolingual angioedema, often asymmetric Airway assessment; stop alteplase; emergency pharmacologic/airway management
Cough, wet voice, hypoxia, fever Dysphagia with aspiration, pneumonia Nil-by-mouth until swallow screen; respiratory and infection assessment

Symptomatic ICH is the most feared thrombolysis complication: in NINDS it occurred within 36 hours in 6.4% with alteplase versus 0.6% with placebo (NINDS rt-PA Stroke Study Group 1995, PMID 7477192). Treatment benefit and hemorrhage risk coexist, so monitoring must not be framed as evidence against reperfusion.

Orolingual angioedema can threaten the airway and has an association with ACE-inhibitor exposure; a case series documented severe, sometimes life-threatening reactions during thrombolysis (Engelter 2005, PMID 16184341). Airway progression can be rapid even when swelling begins focally.

For malignant MCA infarction in adults 18–60, pooled randomized evidence found decompressive surgery within 48 hours reduced mortality from 71% to 22%, but survival includes disability across mRS categories (Vahedi 2007, PMID 17303527). In patients older than 60, DESTINY II increased survival without severe disability (mRS 0–4) from 18% to 38%, but no survivor achieved mRS 0–2 and 32% of surgical survivors had mRS 4 (Jüttler 2014, PMID 24645942). Delay in neurosurgical referral erases the window for an informed values-based choice.

Formal dysphagia screening was associated with markedly lower pneumonia rates across hospitals, independent of stroke severity (Hinchey 2005, PMID 16109909). Screening is not the same as a full swallowing assessment, but oral intake before any screen is an avoidable hazard.

Deterioration after ICH or SAH

Context Red flag Critical causes
ICH Falling GCS, new anisocoria, extensor response Expansion, intraventricular extension, hydrocephalus, herniation
Cerebellar ICH Worsening gait/vertigo followed by drowsiness Brainstem compression or obstructive hydrocephalus
SAH before occlusion Sudden recurrent headache, collapse, abrupt pressure rise Aneurysm rebleeding
SAH days 3–14 New focal deficit or ≥2-point GCS fall lasting ≥1 h DCI after excluding rebleed, hydrocephalus, seizure, infection and metabolic causes
External ventricular drain Headache, reduced drainage, declining consciousness, fever Obstruction, malposition, recurrent hydrocephalus, ventriculitis

ICH expansion is front-loaded; the CTA spot sign identifies higher risk, but a negative study cannot replace serial examination and repeat CT when the patient worsens (Wada 2007, PMID 17322083; Demchuk 2012, PMID 22405630). Corticosteroids should not be used for primary ICH edema; randomized evidence found no mortality benefit and more complications (Poungvarin 1987, PMID 3574383).

After SAH, DCI is a clinical syndrome rather than a Doppler or angiographic label. Consensus requires a new focal deficit or sustained GCS decline not explained by another cause, while imaging infarction is reported separately (Vergouwen 2010, PMID 20798370). Rebleeding and acute hydrocephalus remain emergencies throughout the admission (subarachnoid hemorrhage; Hoh 2023, PMID 37212182).

Medication and procedure safety

Exposure / intervention Principal hazard Evidence boundary
Alteplase / tenecteplase Intracranial hemorrhage, systemic bleeding, orolingual angioedema Benefit declines with delay; contraindications are drug- and context-specific (Powers 2019, PMID 31662037)
Thrombectomy Vessel perforation, dissection, embolization, access-site bleeding, contrast injury HERMES found no significant overall sICH or mortality excess despite procedural risks (Goyal 2016, PMID 26898852)
Antiplatelet combination Major bleeding POINT: 0.9% vs 0.4% major hemorrhage; duration and indication matter (Johnston 2018, PMID 29766750)
Anticoagulation Intracranial/systemic bleeding; accumulation with renal failure; interactions Confirm drug, last dose, renal function, and indication before reversal or resumption
Platelet transfusion in antiplatelet-associated ICH Worse death/dependence in non-surgical spontaneous ICH PATCH does not address thrombocytopenia or planned emergency neurosurgery (Baharoglu 2016, PMID 27178479)
Excessive glucose lowering Severe hypoglycemia and neurological mimic/worsening SHINE: 2.6% severe hypoglycemia with intensive treatment vs 0% standard, no functional gain (Johnston 2019, PMID 31334795)
Routine oxygen in non-hypoxic stroke Treatment burden without benefit SO2S: no 90-day disability or survival benefit (Roffe 2017, PMID 28973619)

Discharge and recurrence red flags

New focal symptoms after discharge are a new emergency, not presumed “post-stroke fluctuation.” Other urgent patterns include a sudden severe headache, seizure, rapidly increasing drowsiness, repeated vomiting, new inability to swallow, aspiration symptoms, falls with head trauma while taking antithrombotics, and signs of major extracranial bleeding. Medication reconciliation must distinguish antiplatelet from anticoagulant drugs, document the indication and intended duration, and detect duplicate therapy.

Recovery-related fatigue, emotional lability, pain, and cognitive fluctuation are common but should not be used to explain a new fixed deficit. Rehabilitation progression must be paused and reassessed when exercise provokes focal neurological symptoms, syncope, chest pain, severe dyspnea, or sustained physiological instability.

Open questions

  • Can public-recognition tools gain posterior-circulation sensitivity without losing the simplicity that makes FAST usable (Harbison 2003, PMID 12511753; Aroor 2017, PMID 28082668)?
  • How can HINTS expertise be scaled safely outside neuro-otology, given its specialist-cohort performance and the risk of misuse in the wrong dizziness population (Kattah 2009, PMID 19762709)?
  • Which low-NIHSS occlusions should trigger immediate thrombectomy transfer before clinical deterioration (Goyal 2016, PMID 26898852)?
  • Can hematoma-expansion prediction become sensitive enough to guide therapy without withholding reversal or monitoring from spot-negative ICH (Demchuk 2012, PMID 22405630)?
  • What combination of rhythm, vessel, brain, and recurrence markers should replace ABCD2-only triage after transient deficits (Johnston 2007, PMID 17258668; Rothwell 2007, PMID 17928046)?

References

  1. Harbison J, et al. Diagnostic accuracy of stroke referrals using the face arm speech test. Stroke. 2003;34:71-76. PMID 12511753.
  2. Aroor S, et al. BE-FAST: reducing the proportion of strokes missed using the FAST mnemonic. Stroke. 2017;48:479-481. PMID 28082668.
  3. Nor AM, et al. The Recognition of Stroke in the Emergency Room (ROSIER) scale. Lancet Neurol. 2005;4:727-734. PMID 16239179.
  4. Kattah JC, et al. HINTS to diagnose stroke in the acute vestibular syndrome. Stroke. 2009;40:3504-3510. PMID 19762709.
  5. Tao C, et al. Trial of endovascular treatment of acute basilar-artery occlusion. N Engl J Med. 2022;387:1361-1372. PMID 36239644.
  6. Jovin TG, et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion. N Engl J Med. 2022;387:1373-1384. PMID 36239645.
  7. Johnston SC, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369:283-292. PMID 17258668.
  8. Rothwell PM, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS). Lancet. 2007;370:1432-1442. PMID 17928046.
  9. Paul NL, et al. Population-based study of capsular warning syndrome and prognosis after early recurrent TIA. Neurology. 2012;79:1356-1362. PMID 22972645.
  10. Wang Y, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11-19. PMID 23803136.
  11. Johnston SC, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379:215-225. PMID 29766750.
  12. Johnston SC, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383:207-217. PMID 32668111.
  13. Ali-Ahmed F, et al. Intravenous tissue plasminogen activator in stroke mimics. Circ Cardiovasc Qual Outcomes. 2019;12:e005609. PMID 31412730.
  14. Markus HS, et al. Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection: CADISS final results. JAMA Neurol. 2019;76:657-664. PMID 30801621.
  15. Saposnik G, et al. Diagnosis and management of cerebral venous thrombosis: an American Heart Association scientific statement. Stroke. 2024;55:e77-e90. PMID 38284265.
  16. Ferro JM, et al. Dabigatran etexilate vs dose-adjusted warfarin in cerebral venous thrombosis (RE-SPECT CVT). JAMA Neurol. 2019;76:1457-1465. PMID 31479105.
  17. Perry JJ, et al. Sensitivity of CT within six hours for diagnosis of subarachnoid haemorrhage. BMJ. 2011;343:d4277. PMID 21768192.
  18. Perry JJ, et al. Clinical decision rules to rule out subarachnoid hemorrhage. JAMA. 2013;310:1248-1255. PMID 24065011.
  19. Wada R, et al. CT angiography spot sign predicts hematoma expansion in acute intracerebral hemorrhage. Stroke. 2007;38:1257-1262. PMID 17322083.
  20. Demchuk AM, et al. Prediction of haematoma growth using the CT-angiography spot sign (PREDICT). Lancet Neurol. 2012;11:307-314. PMID 22405630.
  21. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587. PMID 7477192.
  22. Engelter ST, et al. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J Neurol. 2005;252:1167-1170. PMID 16184341.
  23. Vahedi K, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery. Lancet Neurol. 2007;6:215-222. PMID 17303527.
  24. Jüttler E, et al. Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. N Engl J Med. 2014;370:1091-1100. PMID 24645942.
  25. Hinchey JA, et al. Formal dysphagia screening protocols prevent pneumonia. Stroke. 2005;36:1972-1976. PMID 16109909.
  26. Poungvarin N, et al. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med. 1987;316:1229-1233. PMID 3574383.
  27. Vergouwen MD, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke. 2010;41:2391-2395. PMID 20798370.
  28. Greenberg SM, et al. 2022 Guideline for spontaneous intracerebral hemorrhage. Stroke. 2022;53:e282-e361. PMID 35579034.
  29. Hoh BL, et al. 2023 Guideline for aneurysmal subarachnoid hemorrhage. Stroke. 2023;54:e314-e370. PMID 37212182.
  30. Powers WJ, et al. Guidelines for the early management of acute ischemic stroke: 2019 update. Stroke. 2019;50:e344-e418. PMID 31662037.
  31. Goyal M, et al. Endovascular thrombectomy after large-vessel ischaemic stroke. Lancet. 2016;387:1723-1731. PMID 26898852.
  32. Baharoglu MI, et al. Platelet transfusion versus standard care after antiplatelet-associated spontaneous cerebral haemorrhage (PATCH). Lancet. 2016;387:2605-2613. PMID 27178479.
  33. Johnston KC, et al. Intensive vs standard treatment of hyperglycemia in acute ischemic stroke. JAMA. 2019;322:326-335. PMID 31334795.
  34. Roffe C, et al. Routine low-dose oxygen supplementation after acute stroke. JAMA. 2017;318:1125-1135. PMID 28973619.